Allen Solomon, MD
Clinical Cardiac Electrophysiology · Washington, DCNPI 1033282843
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $124,527 of the $141,728 with a category attached, or 87.9%. Sanofi-aventis U.S. LLC accounts for 71.8% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2021 at $56,271 and has fallen 96.7% since, to $1,830 in 2025.
Across 232 payments — averaging $610.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$102K
- Pfizer$17K
- Johnson & Johnson$11K
- E.r. Squibb & Sons, L.L.C.$4K
- Abbott$4K
- Medtronic$2K
- plus $2K from 20 others
Across 13 payments — averaging $4002.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$52K
What the payments were for
- Consulting fees$6,5605%
- Speaking & faculty fees$124,52788%
- Travel & lodging$4,9473%
- Food & beverage$5,5784%
- Education$1160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 39 | $101,756 |
| Pfizer | 13 | $17,042 |
| Johnson & Johnson | 12 | $10,774 |
| E.r. Squibb & Sons, L.L.C. | 3 | $4,238 |
| Abbott | 54 | $3,994 |
| Medtronic(2 entities) | 56 | $2,374 |
| Edwards Lifesciences | 10 | $453 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $270 |
| Novo Nordisk | 1 | $116 |
| Novartis | 6 | $88 |
| Boston Scientific | 4 | $88 |
| Teleflex LLC | 2 | $66 |
| Cook Medical LLC | 4 | $66 |
| AstraZeneca | 2 | $50 |
| Recor Medical Inc | 2 | $46 |
| Imperative Care, Inc | 1 | $42 |
| Biotronik Inc. | 2 | $37 |
| Bard Peripheral Vascular, Inc. | 2 | $37 |
| W. L. Gore & Associates, Inc. | 2 | $37 |
| BD | 1 | $36 |
| Amgen | 1 | $24 |
| Angiodynamics, Inc. | 1 | $21 |
| Terumo Medical Corporation | 1 | $21 |
| Shockwave Medical, Inc | 1 | $18 |
| Cardiovascular Systems Inc. | 1 | $18 |
| Stryker | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MULTAQ$99,259
- ELIQUIS$20,996
- XARELTO$10,470
- GALLANT$2,200
- AVEIR$801
- Micra$573
- COBALT DR MRI SURESCAN$360
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$298
- Resolute$158
- ONYX FRONTIER$128
- Ozempic$116
- AZURE XT DR MRI SURESCAN$107
How this compares
Too few clinical cardiac electrophysiology providers in District of Columbiato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 464 | $564,258 |
| EntrestoSacubitril/Valsartan | 91 | $124,243 |
| XareltoRivaroxaban | 96 | $102,548 |
| CamzyosMavacamten | 12 | $91,908 |
| JardianceEmpagliflozin | 81 | $76,891 |
| MultaqDronedarone Hcl | 32 | $58,977 |
| Dofetilide | 42 | $11,738 |
| Amiodarone Hcl | 90 | $6,686 |
| Propafenone Hcl ErPropafenone Hcl | 44 | $5,957 |
| Metoprolol Succinate | 267 | $3,891 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 14 | $3,298 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 52 | $1,729 |
| Atorvastatin Calcium | 177 | $1,616 |
| Rosuvastatin Calcium | 91 | $1,447 |
| Ezetimibe | 34 | $1,182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $17,042 | $564,258464 claims |
| NovartisEntresto | $88 | $124,24391 claims |
| Johnson & JohnsonXarelto | $10,774 | $102,54896 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $4,238 | $91,90812 claims |
| Sanofi-aventis U.S. LLCMultaq | $101,756 | $58,97732 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical cardiac electrophysiology providers in District of Columbiaon file to place this against a meaningful peer group, so we don't.
Other clinical cardiac electrophysiology in Washington
- Manish ShahWashington$430K
- Zayd EldadahWashington$358K
- Rajiv KabadiWashington$82K
- Apostolos TsimploulisWashington$28K
- Rohan PatelWashington$20K
- Jay MazelWashington$18K
- Marco MercaderWashington$11K
- Marco CavagnaWashington$5K
- Hans MooreWashington$4K
- Allison WarrenWashington$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.